PapersFlow Research Brief
RNA Interference and Gene Delivery
Research Guide
What is RNA Interference and Gene Delivery?
RNA interference and gene delivery is the set of biological mechanisms and engineered methods used to silence gene expression with small RNAs (e.g., microRNAs or siRNAs) and to transport nucleic-acid payloads into target cells to achieve a desired functional effect.
The research corpus labeled “RNA Interference and Gene Delivery” contains 108,438 works in the provided dataset (5-year growth rate: N/A). “MicroRNAs: Target Recognition and Regulatory Functions” (2009) describes how small RNAs recognize targets and regulate gene expression, providing a mechanistic foundation for RNAi-based silencing. “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” (2007) and “The biology , function , and biomedical applications of exosomes” (2020) establish extracellular vesicles as biologically validated carriers of RNA between cells, linking RNA regulation to delivery biology.
Research Sub-Topics
MicroRNA Target Recognition
This sub-topic investigates miRNA-mRNA binding mechanisms, seed matching rules, and regulatory networks in gene silencing. Researchers develop prediction algorithms and validate interactions experimentally.
CRISPR-Cas9 Genome Editing Delivery
This sub-topic focuses on viral and non-viral vectors for delivering Cas9 and guide RNA into cells for precise gene editing. Researchers optimize efficiency, specificity, and off-target minimization.
Exosome-Mediated RNA Transfer
This sub-topic studies extracellular vesicles transferring miRNAs and mRNAs between cells for intercellular communication. Researchers characterize cargo sorting, uptake mechanisms, and functional impacts.
Lipid Nanoparticle Gene Delivery
This sub-topic develops LNPs for siRNA, mRNA, and CRISPR delivery, optimizing formulations for stability and endosomal escape. Researchers test in vivo pharmacokinetics and immunogenicity.
RNA Interference Off-Target Effects
This sub-topic analyzes unintended silencing from siRNA/miRNA seed-based mismatches and immune activation. Researchers design chemical modifications and bioinformatics filters for specificity.
Why It Matters
RNA interference depends on delivering RNA payloads to the right cells at sufficient intracellular levels, so progress in delivery directly determines whether RNAi can be used in medicines, vaccines, and other applied settings. Real-world translation of nucleic-acid delivery is exemplified by “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” (2020), which reported 94.1% efficacy at preventing Covid-19 illness, demonstrating that systemically administered RNA can achieve clinically meaningful protection when delivery and formulation are effective. Natural RNA carriers also matter: Valadi et al. (2007) showed in “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” that RNAs can move between cells via exosomes, and Kalluri and LeBleu (2020) synthesized biomedical uses of exosomes in “The biology , function , and biomedical applications of exosomes,” framing exosomes as a delivery-relevant platform for RNA cargo. Mechanistically grounded RNA targeting rules from Bartel (2009) in “MicroRNAs: Target Recognition and Regulatory Functions” are directly relevant to designing RNAi triggers with predictable specificity, while cell outcome assays such as Mosmann (1983) in “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” provide standardized readouts to quantify on-target knockdown consequences and delivery-associated toxicity in vitro.
Reading Guide
Where to Start
Start with “MicroRNAs: Target Recognition and Regulatory Functions” (2009) because it lays out the core rules of small-RNA target recognition and regulatory outcomes that underpin how RNAi achieves sequence-specific gene silencing.
Key Papers Explained
Bartel’s “MicroRNAs: Target Recognition and Regulatory Functions” (2009) provides the mechanistic logic for how small RNAs find targets and regulate expression, which is the conceptual basis for designing RNAi reagents. Valadi et al. in “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” (2007) adds a delivery-relevant biological mechanism by showing that RNAs can be transported between cells in exosomes, and Kalluri and LeBleu’s “The biology , function , and biomedical applications of exosomes” (2020) expands that into a biomedical delivery framework. Baden et al. in “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” (2020) demonstrates that RNA delivery can achieve strong clinical performance (94.1% efficacy) when formulation and administration succeed, offering a translational anchor for nucleic-acid delivery. Mosmann’s “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” (1983) provides a practical evaluation tool to quantify whether delivery and gene modulation change viability, while Kerr et al. (1972) and Elmore (2007) provide interpretive context for apoptosis-related outcomes that can follow gene knockdown.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
A practical frontier is integrating mechanistic targeting rules from “MicroRNAs: Target Recognition and Regulatory Functions” (2009) with biologically inspired carriers discussed in “The biology , function , and biomedical applications of exosomes” (2020) and functionally validated RNA transfer in “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” (2007). Another frontier is translating the clinical-scale feasibility implied by “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” (2020) to RNAi contexts by tightening experimental quantification using “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” (1983) and by rigorously attributing phenotypes relative to apoptosis frameworks in “Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics” (1972) and “Apoptosis: A Review of Programmed Cell Death” (2007).
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LI... | 1957 | Journal of Biological ... | 64.3K | ✓ |
| 2 | Rapid colorimetric assay for cellular growth and survival: App... | 1983 | Journal of Immunologic... | 54.7K | ✕ |
| 3 | MicroRNAs: Target Recognition and Regulatory Functions | 2009 | Cell | 20.0K | ✓ |
| 4 | A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Ba... | 2012 | Science | 16.6K | ✓ |
| 5 | Apoptosis: A Basic Biological Phenomenon with Wideranging Impl... | 1972 | British Journal of Cancer | 15.5K | ✓ |
| 6 | Apoptosis: A Review of Programmed Cell Death | 2007 | Toxicologic Pathology | 13.2K | ✓ |
| 7 | Exosome-mediated transfer of mRNAs and microRNAs is a novel me... | 2007 | Nature Cell Biology | 12.5K | ✕ |
| 8 | Genome engineering using the CRISPR-Cas9 system | 2013 | Nature Protocols | 11.4K | ✓ |
| 9 | Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | 2020 | New England Journal of... | 10.3K | ✓ |
| 10 | The biology <b>,</b> function <b>,</b> and biomedical applicat... | 2020 | Science | 9.5K | ✓ |
In the News
Sanegene closes over $110 million series B to advance ...
Sanegene Bio has raised more than $110 million in a series B round to move its RNAi programs toward registration studies and broaden development across metabolic, cardiovascular and autoimmune dise...
SanegeneBio raises $110m for RNAi, plus other financings
**RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series B backed by recent partner Eli Lilly.**
Irish startup Aerska raises €17M to develop RNA ...
Dublin-based biotech firm Aerska has raised €17 million in seed funding to advance systemically delivered RNA interference (RNAi) therapies for brain diseases.
Atalanta Raises $97M to Advance Two Neuro-Targeting ...
Atalanta Therapeutics has netted a $97 million Series B financing to support Phase I clinical trials of the company’s lead investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s...
SenseUP raises $3.5m to advance dsRNA-based ...
SenseUP —a startup developing biopesticides featuring double-stranded RNA (dsRNA) to selectively zap plant pests via RNA interference—has raised €3 million ($3.5 million) in a seed round led by Cap...
Code & Tools
SIREN is a comprehensive toolset for designing RNA interference (RNAi) sequences to silence specific genes while minimizing off‑target effects. It ...
NEXT-RNAi is a software for the design and evaluation of genome-wide RNAi libraries and performs all steps from the prediction of specific and effi...
``` ## About Collection of R packages that work in harmony for CRISPR gRNA design ### Topics
A pipeline for the analysis of CRISPR edited data. It allows the evaluation of the quality of gene editing experiments using targeted next generati...
The `crisprViz` package enables the graphical interpretation of `GuideSet` objects from the crisprDesign package by plotting guide RNA (gRNA) cutt...
Recent Preprints
RNA Therapeutics: Delivery Problems and Solutions—A Review
The discovery of RNA interference (RNAi) mechanisms has significantly boosted the development of RNA-based therapeutics [ 6 ]. A key advancement was understanding how siRNAs can initiate a potent a...
Nanoparticles Used for the Delivery of RNAi-Based Therapeutics
RNA interference (RNAi) offers programmable, sequence-specific silencing via small interfering RNA (siRNA) and microRNA (miRNA), but clinical translation hinges on overcoming instability, immunogen...
Recent advances in nanoparticulate RNA delivery systems
transcribed. Chemically synthesized RNAs, including small interfering RNA (siRNA) for gene knockdown and guide RNAs (gRNAs) for CRISPR-based gene editing, can be made with custom nucleotide modi...
Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
In recent years, RNA interference technology has been extensively studied for its therapeutic potential against a wide variety of diseases. It aims to silence the expression of undesired genes asso...
RNAi - Latest research and news
Systemic RNA interference (RNAi) in _Caenorhabditis elegans_ is initiated by SID-1-mediated double-stranded RNA (dsRNA) internalization. By combining cryo-electron microscopy (cryo-EM), in vitro an...
Latest Developments
Recent developments in RNA interference and gene delivery research include advances in RNA-based therapeutics such as siRNAs, antisense oligonucleotides, and RNA editing technologies like CRISPR-Cas13, with progress in overcoming challenges related to stability, immunogenicity, and targeted delivery, supported by regulatory approvals and ongoing clinical trials as of early 2026 (advancingrna.com; frontiersin.org; globenewswire.com).
Sources
Frequently Asked Questions
What is the mechanistic basis of RNA interference described in the provided papers?
Bartel (2009) in “MicroRNAs: Target Recognition and Regulatory Functions” explains how small RNAs can recognize target sequences and regulate gene expression, which is the mechanistic core that RNAi therapeutics aim to harness. This mechanistic framing is essential for designing silencing reagents whose activity depends on sequence complementarity and target-site context.
How do exosomes relate to RNA delivery for gene regulation?
Valadi et al. (2007) in “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” reported that exosomes can transfer mRNAs and microRNAs between cells, demonstrating a natural route for RNA cargo movement. Kalluri and LeBleu (2020) in “The biology , function , and biomedical applications of exosomes” review exosomes as extracellular vesicles carrying RNA and other biomolecules, positioning them as a delivery-relevant modality.
Which paper provides a clinical example that RNA payload delivery can work at scale in humans?
Baden et al. (2020) in “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” reported 94.1% efficacy at preventing Covid-19 illness, showing that an RNA-based intervention can achieve strong clinical outcomes when delivery and formulation are effective. The same report states that aside from transient local and systemic reactions, no safety concerns were identified.
How can researchers quantify cellular effects when testing RNAi delivery and gene-silencing outcomes?
Mosmann (1983) in “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” describes a rapid colorimetric method widely used to measure proliferation and cytotoxicity. Such assays are commonly used to quantify whether delivery plus RNAi produces intended growth inhibition or unintended toxicity in cell models.
Which highly cited methods papers are commonly used to support RNA delivery experiments even if they are not RNAi-specific?
Folch et al. (1957) in “A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES” is a foundational protocol for lipid isolation that can be relevant when characterizing lipid components associated with delivery systems or biological membranes. Standardized cell-death context is also frequently referenced via Kerr et al. (1972) “Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics” and Elmore (2007) “Apoptosis: A Review of Programmed Cell Death” when interpreting whether RNAi-driven knockdown induces apoptosis.
How is RNA-guided targeting in gene editing different from RNA interference, based on the provided list?
Jínek et al. (2012) in “A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity” and Ran et al. (2013) in “Genome engineering using the CRISPR-Cas9 system” describe RNA-guided DNA cleavage for genome engineering, which changes DNA rather than silencing RNA transcripts. In contrast, Bartel (2009) in “MicroRNAs: Target Recognition and Regulatory Functions” focuses on RNA-mediated regulation of gene expression without requiring DNA cutting.
Open Research Questions
- ? Which exosome cargo-loading and uptake determinants described across “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” (2007) and “The biology , function , and biomedical applications of exosomes” (2020) most strongly control functional delivery of regulatory RNAs in recipient cells?
- ? Which target-site features emphasized in “MicroRNAs: Target Recognition and Regulatory Functions” (2009) best predict when an RNAi trigger will cause potent silencing versus minimal effect in a given cellular context?
- ? How can delivery-associated cytotoxicity be disentangled from on-target gene-silencing phenotypes using standardized viability readouts from “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” (1983)?
- ? Which experimental criteria should be used to distinguish RNA-transfer-mediated phenotypes from apoptosis-driven secondary effects, given the canonical apoptosis frameworks in “Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics” (1972) and “Apoptosis: A Review of Programmed Cell Death” (2007)?
- ? What generalizable formulation and deployment lessons from population-scale RNA delivery in “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” (2020) can be translated to RNAi payloads while maintaining acceptable tolerability?
Recent Trends
Within the provided dataset, the topic is large (108,438 works; 5-year growth rate: N/A), and the most-cited anchors emphasize (i) mechanistic RNA regulation (“MicroRNAs: Target Recognition and Regulatory Functions” ), (ii) biologically validated intercellular RNA transport via vesicles (“Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells” (2007)), and (iii) applied biomedical deployment of RNA platforms (“Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine” (2020), reporting 94.1% efficacy).
2009The prominence of exosome-focused synthesis (“The biology , function , and biomedical applications of exosomes” ) alongside clinical RNA delivery outcomes suggests increasing convergence between RNA regulation biology and delivery-centric translational work, with experimental evaluation commonly grounded in standardized viability assays such as Mosmann (1983) “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays.”.
2020Research RNA Interference and Gene Delivery with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching RNA Interference and Gene Delivery with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.